Accordingly, Cetuximab treatment of this subgroup of R/M-HNSCC patients has a beneficial therapeutic impact as it suppresses progression-relevant aspects of EGFR signaling. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.